Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E coli vaccine in healthy adults
NCT07122986Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Primary completion
- May 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07923567 in Escherichia coli infection (10 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting prespecified local events, Percentage of participants reporting prespecified systemic events and 3 more. Started Aug 2025; status: active, not recruiting.
02
Drugs
PF-07923567
03
Conditions
Escherichia coli infection
Beyond the preview
Go deeper on NCT07122986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122986.